News | Breast Density | January 13, 2016

More Research Needed on Evaluation of Dense Breasts

Literature review finds density determinations can be unreliable and inconsistent; benefit of additional screening also questioned

breast density, evaluation, BI-RADS, unreliable, UC Davis study

January 13, 2016 — A systematic review of scientific literature on dense breasts by researchers at the University of California (UC) Davis and other institutions has found breast density determinations can be unreliable. Researchers discovered as many as 19 percent of women are re-categorized as dense rather than non-dense or vice versa from one mammogram to the next. The study also found that supplemental diagnostic screenings for women with dense breasts find additional breast cancers but also greatly increase false positive results.

The review of 24 studies among 2,067 citations examined the evidence on the consistency of breast density category assignment and on supplemental screening beyond standard mammography for women with dense breasts. The review, supported by the Agency for Healthcare Research and Quality, was published in the Annals of Internal Medicine.

“The number of states mandating that breast density information be reported to patients is increasing,” said Joy Melnikow, who directs the Center for Healthcare Policy and Research at UC Davis and was first author on the paper. “But the assignment of breast density is not terribly consistent. The policy may be out in front of the science.”

Breast density has been categorized through the Breast Imaging Reporting and Data System (BI-RADS). Breasts are defined as: a) mostly fatty, b) scattered density, c) consistent density and d) extremely dense. Higher breast density modestly increases a woman’s risk of developing breast cancer and decreases the sensitivity and specificity of screening mammograms. Women classified with dense breasts (categories c and d) may be offered supplemental screening with ultrasound or magnetic resonance imaging (MRI). However, the study shows this approach may not be supported by strong scientific evidence.

The first problem is the inability to accurately assess whether a woman has dense breasts to begin with. One study showed that different radiologists assigned the same BI-RADS category to an individual woman only 82 percent of the time. Other data showed that as many as 22 percent of women were reclassified from dense to non-dense (on vice versa) on consecutive mammograms.

“It is important to be clear who actually has dense breasts,” said Melnikow. “Also, when patients are told their breasts are either dense or not dense, they need to have confidence in that assessment.”

Additional diagnostic tests for women thought to have dense breasts will find some additional breast cancers; however, there were no studies that examined women’s long-term health outcomes after supplemental screening beyond diagnosis.

“It’s clear from our review of ultrasound and MRI that if you go beyond mammography to try to find breast cancers you can find them,” said Melnikow. “But whether there’s a benefit to women’s health from looking is not established. At this point, there are no studies on clinical outcomes.”

Melnikow believes the best solution for these problems is to conduct long-term, rigorous research to better standardize breast density classification and determine whether supplemental screenings provide actual health benefits for women. The U.S. Preventive Services Task Force, in their recommendation statement published in the same issue of Annals of Internal Medicine, found insufficient evidence to assess the balance of benefits and harms for supplemental screening of women with dense breasts with ultrasound, MRI or other modalities.

“It’s important that policies come from the evidence,” said Melnikow. “It’s also important that women not overreact to information about their breast density.”

Other authors included: Joshua J. Fenton, Diana L. Miglioretti and Meghan S. Weyrich at UC Davis; Evelyn P. Whitlock and Jamie H. Thompson at Kaiser Permanente Northwest; and Kunal Shah at Columbia University.

This research was funded by the Agency for Healthcare Research and Quality (HHSA-290-2012-00015I).

For more information: www.annals.org

Related Content

Fujifilm Installing New DR Equipment for Three Large Healthcare Systems
News | Digital Radiography (DR) | September 22, 2017
Fujifilm Medical Systems U.S.A. Inc. recently closed new contracts to enhance diagnostic imaging capabilities for...
Theraclion to Launch Metastatic Breast Cancer Trial Combining Echotherapy and Immunotherapy
News | Focused Ultrasound Therapy | September 18, 2017
September 18, 2017 — Theraclion and co-lead investigator David Brenin, M.D., from the University of Virginia School o
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
DenseBreast-info.org Debuts  Spanish Language Video  About Dense Breasts
News | Breast Density | September 12, 2017
Breast cancer risks associated with breast density are the subject of a new Spanish language video launched recently by...
Asian Study Underlines Potential Value of Pressure-Guided Mammography
News | Mammography | September 11, 2017
Sigmascreening recently announced that a study of in total 15,898 in digital mammograms from 3,772 Asian women...
Delphinus Enrolls First Patient in Discover Breast Ultrasound Clinical Project
News | Ultrasound Womens Healthcare | September 08, 2017
September 8, 2017 — Delphinus Medical Technologies Inc.
Breast imaging X-ray mammogram showing a breast tumor. Photo courtesy of Monthian Ritchan-Ad

Photo courtesy of Monthian Ritchan-Ad

Feature | Breast Density | September 08, 2017 | By Roy Prager, M.D.
While mammograms play a vital role in efforts to identify breast cancer, they can present some challenges in women with...
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Overlay Init